FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283713274> ?p ?o ?g. }

• W4283713274 endingPage "1617" @default.
• W4283713274 startingPage "1616.2" @default.
• W4283713274 abstract "Background There is an unmet need for new treatments for hand osteoarthritis (OA). Symptomatic hand OA is more common in women and its incidence increases round the age of menopause. Pre-clinical, epidemiological and post hoc studies in Hormone Replacement Therapy (HRT) trials implicate estrogen deficiency as of likely importance in OA aetiopathogenesis. No clinical trials of HRT have been carried out in hand OA to date. The licensed HRT Duavive (conjugated estrogens + SERM bazedoxifene) was selected on its potential for efficacy and tolerability. Objectives We set out to determine the feasibility and acceptability of this form of HRT in post-menopausal women with hand OA, to generate proof of concept data and refine methods for a full study. Methods ISRCTN12196200. Females aged 40-65 yrs and 1-10yrs after final menstrual period with hand OA fulfilling ACR criteria and 2+ painful hand joints were recruited. Eligibility incorporated best practice for HRT prescription but did not require menopausal symptoms. Recruitment was at 3 sites in primary/secondary care, including directly from the community. Design was parallel group, double-blind 1:1 randomisation of Duavive or placebo, orally once daily for 24 weeks, then weaning for 4 weeks before stopping. Routes and rates of recruitment and the acceptability of randomisation, medication (compliance, retention), and proposed outcomes were measured, and the likelihood of unblinding. Measures related to hand pain and function, menopause symptoms and joint appearance. Patient and Public Involvement actively informed study rationale, design and materials. An end of study questionnaire and 2 participant focus groups provided further acceptability data. Results Recruitment was for 12/possible 18 months, interrupted due to COVID-19. Some study procedures were modified to allow reopening whilst collecting all primary outcomes. 434 enquiries/referrals were received, leading to 96 telephone pre-screens, of which 33 gave written informed consent and attended face to face screening. 28/33 screened (85%) were eligible and randomised. The highest number of randomisations was from study web presence (n=7) followed by SMS text from GP surgeries (n=5). Of 401 not proceeding, 250 (62%) were ineligible, most commonly due to contraindicated medication, followed by medical contraindication, whilst 55 (14%) decided not to take part, for reasons including not wanting to take a hormone-based drug or difficulty attending study visits. Retention and compliance were excellent. All 28 participants completed all study follow ups, with only 3 withdrawals from treatment due to AEs, 2 of these at week 24 and all in the placebo arm. There were no serious AEs. High levels of completeness of all study outcome measures were achieved. Bang’s blinding index suggested that participants/investigators were well blinded. There were overall high/good levels of satisfaction with taking part in the study. 26/28 (92%) would recommend taking part to others with hand OA (irrespective of study arm). Many found the flexibility offered by a combination of remote and face to face visits (due to the pandemic) attractive. Additional insights from focus groups were to include hand stiffness as well as pain measures but to reduce the overall number of questions. Conclusion Despite COVID-19 and a reduced recruitment period, this study recruited sufficient numbers to assess feasibility outcomes. Randomisation of eligible people and retention rates were high. A mixture of remote and face to face visits due to COVID-19 probably improved recruitment and retention and was supported by participants, who were generally satisfied with the study design and medication. The study provided useful insight and improvements that would be incorporated into a future study. Overall, this feasibility study showed that with clear messaging on eligibility and a defined recruitment strategy, recruitment and retention to a study testing this treatment is possible. Acknowledgements This research was funded by the National Institute for Health Research (NIHR) under its Research for Patient Benefit (RfPB) Programme (Grant Reference Number PB-PG-0416-20023). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. The study team thank the sites and the participants who made this research possible. Disclosure of Interests Jennifer A.E. Williams: None declared, Mae Chester-Jones: None declared, Anne Francis: None declared, Ioana Marian: None declared, Megan Goff: None declared, Gretchen Brewer: None declared, Malvika Gulati: None declared, Lucy Eldridge: None declared, Patrick Julier: None declared, Catherine Minns Lowe: None declared, Vicki Barber: None declared, Victoria Glover: None declared, Charles Mackworth-Young: None declared, Tonia Vincent Consultant of: Pfizer, Grant/research support from: Grant support from Fidia, Biosplice, Novartis, Pfizer as part of their contribution to an international consortium., Sarah E Lamb: None declared, Katy Vincent: None declared, Susan J Dutton: None declared, Fiona E Watt Consultant of: Pfizer, Grant/research support from: Pfizer and from Astellas Pharma (> 3 years ago)" @default.
• W4283713274 created "2022-06-30" @default.
• W4283713274 creator A5004961773 @default.
• W4283713274 creator A5007944409 @default.
• W4283713274 creator A5008998512 @default.
• W4283713274 creator A5009001077 @default.
• W4283713274 creator A5012121920 @default.
• W4283713274 creator A5016410960 @default.
• W4283713274 creator A5017455354 @default.
• W4283713274 creator A5036557991 @default.
• W4283713274 creator A5037756434 @default.
• W4283713274 creator A5047490896 @default.
• W4283713274 creator A5047802959 @default.
• W4283713274 creator A5053821573 @default.
• W4283713274 creator A5055877764 @default.
• W4283713274 creator A5062402035 @default.
• W4283713274 creator A5071024014 @default.
• W4283713274 creator A5081242915 @default.
• W4283713274 creator A5085053413 @default.
• W4283713274 creator A5088507632 @default.
• W4283713274 date "2022-05-23" @default.
• W4283713274 modified "2023-09-27" @default.
• W4283713274 title "AB0980 Hand Osteoarthritis: investigating Pain Effects in a randomised placebo-controlled feasibility study of estrogen-containing therapy (HOPE-e): report on the primary feasibility outcomes" @default.
• W4283713274 doi "https://doi.org/10.1136/annrheumdis-2022-eular.2437" @default.
• W4283713274 hasPublicationYear "2022" @default.
• W4283713274 type Work @default.
• W4283713274 citedByCount "0" @default.
• W4283713274 crossrefType "journal-article" @default.
• W4283713274 hasAuthorship W4283713274A5004961773 @default.
• W4283713274 hasAuthorship W4283713274A5007944409 @default.
• W4283713274 hasAuthorship W4283713274A5008998512 @default.
• W4283713274 hasAuthorship W4283713274A5009001077 @default.
• W4283713274 hasAuthorship W4283713274A5012121920 @default.
• W4283713274 hasAuthorship W4283713274A5016410960 @default.
• W4283713274 hasAuthorship W4283713274A5017455354 @default.
• W4283713274 hasAuthorship W4283713274A5036557991 @default.
• W4283713274 hasAuthorship W4283713274A5037756434 @default.
• W4283713274 hasAuthorship W4283713274A5047490896 @default.
• W4283713274 hasAuthorship W4283713274A5047802959 @default.
• W4283713274 hasAuthorship W4283713274A5053821573 @default.
• W4283713274 hasAuthorship W4283713274A5055877764 @default.
• W4283713274 hasAuthorship W4283713274A5062402035 @default.
• W4283713274 hasAuthorship W4283713274A5071024014 @default.
• W4283713274 hasAuthorship W4283713274A5081242915 @default.
• W4283713274 hasAuthorship W4283713274A5085053413 @default.
• W4283713274 hasAuthorship W4283713274A5088507632 @default.
• W4283713274 hasBestOaLocation W42837132741 @default.
• W4283713274 hasConcept C121608353 @default.
• W4283713274 hasConcept C126322002 @default.
• W4283713274 hasConcept C142724271 @default.
• W4283713274 hasConcept C1862650 @default.
• W4283713274 hasConcept C197934379 @default.
• W4283713274 hasConcept C204787440 @default.
• W4283713274 hasConcept C27081682 @default.
• W4283713274 hasConcept C2776164576 @default.
• W4283713274 hasConcept C2778375690 @default.
• W4283713274 hasConcept C2778562196 @default.
• W4283713274 hasConcept C2779279991 @default.
• W4283713274 hasConcept C2780159708 @default.
• W4283713274 hasConcept C2780932660 @default.
• W4283713274 hasConcept C530470458 @default.
• W4283713274 hasConcept C535046627 @default.
• W4283713274 hasConcept C71924100 @default.
• W4283713274 hasConceptScore W4283713274C121608353 @default.
• W4283713274 hasConceptScore W4283713274C126322002 @default.
• W4283713274 hasConceptScore W4283713274C142724271 @default.
• W4283713274 hasConceptScore W4283713274C1862650 @default.
• W4283713274 hasConceptScore W4283713274C197934379 @default.
• W4283713274 hasConceptScore W4283713274C204787440 @default.
• W4283713274 hasConceptScore W4283713274C27081682 @default.
• W4283713274 hasConceptScore W4283713274C2776164576 @default.
• W4283713274 hasConceptScore W4283713274C2778375690 @default.
• W4283713274 hasConceptScore W4283713274C2778562196 @default.
• W4283713274 hasConceptScore W4283713274C2779279991 @default.
• W4283713274 hasConceptScore W4283713274C2780159708 @default.
• W4283713274 hasConceptScore W4283713274C2780932660 @default.
• W4283713274 hasConceptScore W4283713274C530470458 @default.
• W4283713274 hasConceptScore W4283713274C535046627 @default.
• W4283713274 hasConceptScore W4283713274C71924100 @default.
• W4283713274 hasIssue "Suppl 1" @default.
• W4283713274 hasLocation W42837132741 @default.
• W4283713274 hasLocation W42837132742 @default.
• W4283713274 hasOpenAccess W4283713274 @default.
• W4283713274 hasPrimaryLocation W42837132741 @default.
• W4283713274 hasRelatedWork W1556335090 @default.
• W4283713274 hasRelatedWork W1966031956 @default.
• W4283713274 hasRelatedWork W1990986050 @default.
• W4283713274 hasRelatedWork W2008306744 @default.
• W4283713274 hasRelatedWork W2019989482 @default.
• W4283713274 hasRelatedWork W2068786447 @default.
• W4283713274 hasRelatedWork W2574257386 @default.
• W4283713274 hasRelatedWork W3035431056 @default.
• W4283713274 hasRelatedWork W9372330 @default.
• W4283713274 hasRelatedWork W2340667129 @default.
• W4283713274 hasVolume "81" @default.
• W4283713274 isParatext "false" @default.
• W4283713274 isRetracted "false" @default.
• W4283713274 workType "article" @default.